| Literature DB >> 36012269 |
Chao Lu1, Etienne Joulin1, Howyn Tang2, Hossein Pouri1, Jin Zhang1,2.
Abstract
Upconversion (UC) nanostructures, which can upconvert near-infrared (NIR) light with low energy to visible or UV light with higher energy, are investigated for theranostic applications. The surface of lanthanide (Ln)-doped UC nanostructures can be modified with different functional groups and bioconjugated with biomolecules for therapeutic systems. On the other hand, organic molecular-based UC nanostructures, by using the triplet-triplet annihilation (TTA) UC mechanism, have high UC quantum yields and do not require high excitation power. In this review, the major UC mechanisms in different nanostructures have been introduced, including the Ln-doped UC mechanism and the TTA UC mechanism. The design and fabrication of Ln-doped UC nanostructures and TTA UC-based UC nanostructures for theranostic applications have been reviewed and discussed. In addition, the current progress in the application of UC nanostructures for diagnosis and therapy has been summarized, including tumor-targeted bioimaging and chemotherapy, image-guided diagnosis and phototherapy, NIR-triggered controlled drug releasing and bioimaging. We also provide insight into the development of emerging UC nanostructures in the field of theranostics.Entities:
Keywords: NIR-triggered drug delivery; biosensing; drug carriers; lanthanide-doped upconversion nanoparticles; metal-organic frameworks; theranostic system; triplet-triplet annihilation upconversion; upconversion nanomaterials
Mesh:
Substances:
Year: 2022 PMID: 36012269 PMCID: PMC9409402 DOI: 10.3390/ijms23169003
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1Skin penetration depth of light with different wavelengths [11,12].
Figure 2(A) Scheme of upconversion mechanisms. (a). ESA: Excited State Absorption, (b). Energy Transfer upconversion, (c). Cross Relaxation. G: ground state. E1: intermediate state. E2: excited state. Red line: photo excitation process. Blue line: emission process. Yellow dashed line: energy transfer process. (B) The wavelength of the emitted photons from the transition of lanthanide ions can be varied from 400 nm to 700 nm (as is shown in color bar), which shows the tunability of different lanthanide ions (reproduced with permission from [16]).
Figure 3Dye-sensitized upconversion mechanisms and the typical structure of dye-sensitized upconversion (UC) nanostructures. (A) Schematic illustrations of dye-sensitized upconversion (1S*: single state, 3T*: triplet excited state, yellow line: nonradiative energy transfer, blue line: upconversion emission). (B) (a) Typical structure of dye-sensitized UC nanostructures in which only one type of sensitizer is contained. (b) Typical structure of dye-sensitized core/shell UC nanostructures, in which two different sensitizers were used (S: sensitizer, A: activator) (reproduced with permission from [23]).
Figure 4Scheme of the anti-stokes process of triplet-triplet annihilation upconversion nanoparticles (1S*: single state, 3T*: triplet-excited state, ISC: intersystem crossing process).
Summary of the composition and surface modification strategies of Upconversion nanostructures for biomedical applications and their theranostic applications. UCL: upconversion luminescence, MRI: magnetic resonance imaging, CT: computerized tomography, PTT: photothermal therapy, PDT: photodynamic therapy, PEG: polyethylene glycol, UV: ultraviolet, MOFs: metal-organic frameworks.
|
|
|
|
|
| |
|---|---|---|---|---|---|
|
|
| ||||
| Mesoporous silica coating | NaYF4:20%Yb,2%Er@NaGdF4 NPs | Loading cis-platinum pro-drugs and cytotoxic protein ribonuclease A for RNA-targeted tumor therapy and proteins-based therapies. | HepG2 cells | H22 tumor-bearing Balb/c mice (UCL and T1-weighted MRI) | [ |
| NaYF4:17%Yb,3%Er NPs | Adsorption of ibuprofen. | HeLa cells | - | [ | |
| NaYF4:25%Yb,2%Er,0.5%Tm NPs | Rose Bengal and zinc(II)phthalocyanine for PDT. | HeLa cells | - | [ | |
| NaGdF4:20%Yb,2%Er@NaGdF4:30%Nd,10%Yb | Chlorin e6 and merocyanine 540 for PDT. | HeLa cells | U14 tumor-bearing Balb/c mouse (UCL and CT imaging) | [ | |
| NaGdF4:18%Yb,2%Er@NaGdF4: | Rose Bengal for PDT. Conjugation with Linker-Protein G for tumor targeting. | HT-29 cells | - | [ | |
| Silica and manganese dioxide coating, PEGylated surface | NaGdF4:20%Yb,2%Er@ NaGdF4:20%Yb NPs | Loading DOX for chemotherapy. Loading chlorin e6 for PDT. | HeLa cells | U14 tumor bearing mice (UCL, T1-weighted MR and CT imaging) | [ |
| Silica and manganese dioxide coating | NaGdF4:19%Yb,1%Er,1%Tm@NaGdF4:10%Yb@NaNdF4:10%Yb | Chlorin e6 for PDT. | L929 cells and HeLa cells | U14 tumor-bearing Kunming mice (UCL, T1-weighted MR and CT imaging) | [ |
| Silica and cerium oxide coating, PEGylated surface | NaGdF4:20%Yb,1%Tm@NaGdF4 | Cerium oxide for PDT. DOX for chemotherapy. | L929 cells and HeLa cells | U14 tumor-bearing mice. (UCL, T1-weighted MR and CT imaging) | [ |
| Silica coating, followed by hyaluronic acid modification | NaYF4:20%Yb,2%Er | Titanium dioxide and DOX for sonodynamic therapy and chemotherapy, respectively. | KB and MCF-7 cells | S180 tumor-bearing mice (UCL) | [ |
| Silica coating, PEGylated surface | NaYF4:24.7%Yb,0.3%Tm NPs | DOX for chemotherapy.Folic acid for tumor targeting. | HeLa cells | HeLa cells of tumor-bearing nude mice (UCL) | [ |
| PEGylated | Y2O3:Yb3+/Er3+ hollow nanospheres | DOX loaded for chemotherapy. | HeLa cells | UCL imaging in anaesthetized white ICR mice (UCL) | [ |
| NaGdF4Yb/Nd@NaGdF4:Yb/Er@NaGdF4 | Rose Bengal for PDT, and Pt(IV) prodrugs for chemotherapy. | A2780 cells | - | [ | |
| NaYF4:18%Yb,0.6%Tm@NaYF4 | Resonant excitation 2F5/2 → 2F7/2 of Yb3+ for PTT. | A375 and HEK 293 cells | A375 Male Balb/c nu/nu mice | [ | |
| NaGdF4:20%Yb,2%Er@NaGdF4:25%Yb,25%Nd | Cerium oxide for PDT. Nanographene oxide for PTT. | L929 cells and HeLa cells | U14 tumor bearing mice (UCL imaging) | [ | |
| NaYF4:20%Yb,2%Er | protoporphyrin IX for PDT. Conjugate to AS1411 for cancerous cells targeting. | MCF-7 and HeLa cells | - | [ | |
| NaYF4:27%Yb,2%Er | Phthalocyanine zinc for PDT. Conjugate with Gefitinib (G) to target the ATP binding domain of the tyrosine kinase. | HepG2 cells and HELF cells | - | [ | |
| PEG and folic acid-modified | NaYF4:25%Yb,0.3%Tm NPs | DOX for chemotherapy. MoS2 for PDT. | HeLa and HepG2 cells | - | [ |
| Stabilization by polyetherimide, followed by PEG modification | NaGdF4:40%Yb,0.5%Tm@NaGdF4:2%Yb NPs | ZnFe2O4 for PDT. Pt(IV) prodrugs for Glutathione-mediated cancer cell killing. | HeLa cells | U14 cells (cervical carcinoma cells) of female Balb/c mice (UCL) | [ |
| NaYF4:40%Yb,0.5%Tm@NaGdF4:2%Yb NPs | Trans-platinum(IV) prodrug triggered by upconverted emission UV light. | HeLa cells | H22 tumor-bearing female Balb/c mice (UCL) | [ | |
| NaGdF4:17%Yb,3%Er NPs | Platinum(IV) prodrug for chemotherapy. Delivery of siRNA to the silence gene (eukaryotic translation initiation factor 4E). | Hep-2 cells and L929 cells | Anesthetized Balb/C nude mice (UCL) | [ | |
| Stabilization by polyetherimide, followed by chitosan wrapped surface | NaYF4:Yb/Er | Pyropheophorbide a for PDT. Conjugate with RGD peptide c for targeting. | U87-MG cells | - | [ |
| Polyetherimide-modified | NaYF4:20%Yb,2%Er hollow nanospheres | DOX for chemotherapy. | KB cells | - | [ |
| NaGdF4:17%Yb,3%Er NPs | Delivery of bcl-2 siRNA for gene therapy for tumors. | HeLa cells | Anesthetized Kunming mouse (UCL, T1-weighted MR and CT imaging) | [ | |
| Surface coated by TWEEN | NaYF4:20%Yb,2%Er @ NaYF4 NPs | Doxorubicin (DOX) loaded for chemotherapy. | HeLa cells. | - | [ |
| Transferrin-coated | NaYF4:30%Gd,18%Yb,2%Er NPs | Protoporphyrin IX for PDT. Magnetically assisted tumor cell targeting. | MDA-MB-231 and HeLa cells | - | [ |
| Alpha-cyclodextrin-modified | CaF2:20%Yb,2%Er NPs | DOX for chemotherapy. | HeLa cells | Anaesthetized Kunming mouse (UCL and CT imaging) | [ |
| Surface functionalized by 15-carboxy-N,N,N-trialkylpentadecan-1-ammonium bromide | NaYF4:Yb/Er@ NaGdF4 NPs | DOX for chemotherapy. pH responsive. | HeLa cells | - | [ |
| Gelatin-modified | BaGdF5:20%Yb3+,2%Tm3+@BaGdF5:x%Yb3+ Ultra-small NPs | DOX for chemotherapy. pH triggered drug releasing. | HeLa cells | Anesthetized white Kunming mice (UCL) | [ |
| Polysaccharide polymer (guar gum)-coated | NaYF4:20%Yb,2%Er@ NaYbF4 NPs | Rose Bengal for PDT. 5-fluorouracil for chemotherapy. Target releasing in the colon. | HT-29 colon carcinoma cells | - | [ |
| Poly(acrylic acid)-modified | NaYF4:18%Yb,2%Er@NaYF4:10%Yb NPs | DOX for chemotherapy. | MCF-7 cells | H22 tumor-bearing female Kunming mice (UCL) | [ |
| Citric acid modification, followed by a growing gold shell on the surface | NaYF4:20%Yb,2%Er@NaGdF4 NPs | DOX for chemotherapy. Gold shell for PTT. | HeLa cells | - | [ |
| Formation of MOFs on the surface | NaYF4:20%Yb,1.5%Er,0.5%Tm NPs | DOX and 5-fluorouracil for chemotherapy. | HeLa cells | - | [ |
| Formation of MOFs(MIL-53-NH2) on the surface, and PEG-functionalized | NaGdF4:20%Yb,2%Er@NaGdF4:30%Nd NPs | DOX loaded for chemotherapy. Folic acid for tumor targeting. | HeLa cells | - | [ |
| Formation of Zr (IV)-based porphyrin MOFs on the core surface | NaYbF4:80%Er@NaGdF4:20%Yb,2%Er@NaGdF4 | The composition of MOFs (Zr6 clusters) for PDT. Conjugated with anti-programmed death ligand 1 for immunotherapy. | CT26 cells | CT26 tumor-bearing female BALB/c mice (NIR-II imagining) | [ |
| Encapsulation into MOFs (UiO-68-NH2) | NaGdF4:20%Yb,2%Er@NaGdF4:40%Nd,10%Yb NP | Chlorin e6 and Rose Bengal for PDT. | 4T1 cells | 4T1 tumor-bearing female Balb/C mice | [ |
| Encapsulation into nano-phospholipids | NaYF4:20%Yb,2%Er NPs. | Loading various PDT reagents. | HeLa cells, KB cells and REF52 cells | - | [ |
| Encapsulation into liposomes | NaYF4:60%Yb,2%Er | DOX and methylene blue for chemotherapy and PDT, respectively. Conjugated to the anti-HER2 peptide to target breast cancer cells. | SKBR-3 breast cancer cell lines | - | [ |
| NaGdF4:20%Yb,2%Er | Loading docetaxel for treating gliomas. | C6 glioma cells | - | [ | |
Figure 5Chemical structures of photosensitizers for photodynamic therapy (PDT) (add MB and ZnPc).
Figure 6(A) Schematic illustration of NaLnF4@MOF in a cell for NIR-triggered photodynamic therapy and NIR-II bioimaging for diagnosis. (B) NIR-II images of BALB/c tumor-bearing mice treated with NaLnF4@MOF nanoparticles after intratumoral injection (0 min, 5 min, 4 h, 24 h and 72 h). (C) The images and (D) mass of excised tumors after two weeks post-injection (HEPES is the buffer solution as a control, *** p < 0.001) (Reprinted with permission from [84]).
Figure 7Scheme of the mechanism of the light-triggered drug vehicles (administered by intravenous injection and triggered by light when approaching the targeted sites).
Figure 8Schematic illustration of the NIR-triggered theranostic system and its effect on controlled release and image-guided diagnosis. (A) Structure of SiO2-coated upconversion (UC) nanostructures and the detailed structure of pore orifices anchored with supramolecular valves. (B) NIR-triggered release mechanism. (C) Doxorubicin (DOX) releasing profile under dark and different NIR irradiation dosages (1.0–1.9 W cm–2). (D) In vivo UCL imaging of a tumor-bearing Balb/c mouse: pre-injection, post-injection and 24 h post-injection (from the left to the right). Reproduced with permission from [137].